Hemostemix Inc. (CVE:HEM – Get Free Report) shares rose 23.8% during mid-day trading on Wednesday . The company traded as high as C$0.13 and last traded at C$0.13. Approximately 356,000 shares traded hands during mid-day trading, an increase of 1% from the average daily volume of 351,835 shares. The stock had previously closed at C$0.11.
Hemostemix Price Performance
The firm has a market cap of C$20.91 million, a P/E ratio of -12.00 and a beta of 0.20. The stock’s 50-day simple moving average is C$0.09 and its two-hundred day simple moving average is C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- Stock Splits, Do They Really Impact Investors?
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Why Invest in High-Yield Dividend Stocks?
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- There Are Different Types of Stock To Invest In
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
